source
- Amgen deploys patients to defend troubled Tavneos in FDA hearing requestFacing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.BioSpace · 5d ago↗ source
- Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealPlus news about Abbvie and Genmab, Johnson & Johnson and Mannkind. Novo urges court to block Lilly’s GLP-1 ads: Novo Nordisk asked a New Jersey federal court on Friday to temporarily block what it…Endpoints · 5d ago↗ source
- STAT+: Fatal gene-editing trial in China raises ethics and oversight questionsSanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout